By performing a comprehensive plasma complement protein profiling, we found significant changes in C2, C3, C5, C3b, and C5a in AChR-MG patients compared to healthy controls, suggesting the potential value of these proteins as complement-related biomarkers for MG. The gene discussed is C5; the disease is myasthenia gravis.